Search

Your search keyword '"Roy, Sabita"' showing total 346 results
Start Over Author "Roy, Sabita" Publication Year Range Last 10 years
346 results on '"Roy, Sabita"'

7. STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets

Author

Bader, Cameron S, Barreras, Henry, Lightbourn, Casey O, Copsel, Sabrina N, Wolf, Dietlinde, Meng, Jingjing, Ahn, Jeonghyun, Komanduri, Krishna V, Blazar, Bruce R, Jin, Lei, Barber, Glen N, Roy, Sabita, and Levy, Robert B

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Prevention, Stem Cell Research - Nonembryonic - Non-Human, Rare Diseases, Transplantation, Stem Cell Research, Inflammatory and immune system, Good Health and Well Being, Animals, Bone Marrow Transplantation, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mice, T-Lymphocyte Subsets, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

The stimulator of interferon genes (STING) pathway has been proposed as a key regulator of gastrointestinal homeostasis and inflammatory responses. Although STING reportedly protects against gut barrier damage and graft-versus-host disease (GVHD) after major histocompatibility complex (MHC)-mismatched allogeneic hematopoietic stem cell transplantation (aHSCT), its effect in clinically relevant MHC-matched aHSCT is unknown. Studies here demonstrate that STING signaling in nonhematopoietic cells promoted MHC-matched aHSCT-induced GVHD and that STING agonists increased type I interferon and MHC I expression in nonhematopoietic mouse intestinal organoid cultures. Moreover, mice expressing a human STING allele containing three single-nucleotide polymorphisms associated with decreased STING activity also developed reduced MHC-matched GVHD, demonstrating STING's potential clinical importance. STING-/- recipients experienced reduced GVHD with transplant of purified donor CD8+ T cells in both MHC-matched and MHC-mismatched models, reconciling the seemingly disparate results. Further examination revealed that STING deficiency reduced the activation of donor CD8+ T cells early after transplant and promoted recipient MHC class II+ antigen-presenting cell (APC) survival. Therefore, APC persistence in STING pathway absence may account for the increased GVHD mediated by CD4+ T cells in completely mismatched recipients. In total, our findings have important implications for regulating clinical GVHD by targeting STING early after aHSCT and demonstrate that an innate immune pathway has opposing effects on the outcome of aHSCT, depending on the donor/recipient MHC disparity.

Published
2020

14. Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection

Author

Carrico, Adam W, Cherenack, Emily M, Roach, Margaret E, Riley, Elise D, Oni, Olorunleke, Dilworth, Samantha E, Shoptaw, Steven, Hunt, Peter, Roy, Sabita, Pallikkuth, Suresh, and Pahwa, Savita

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Substance Misuse, Drug Abuse (NIDA only), Sexually Transmitted Infections, Brain Disorders, HIV/AIDS, Methamphetamine, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, CD4 Lymphocyte Count, Central Nervous System Stimulants, Cocaine, Cross-Sectional Studies, Disease Progression, HIV Infections, Humans, Interleukin-6, Male, Middle Aged, Monocytes, Randomized Controlled Trials as Topic, Substance-Related Disorders, Young Adult, alcohol, cocaine, HIV, immune activation, methamphetamine, microbial translocation, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveMicrobial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes.DesignCross-sectional study at baseline for a randomized controlled trial.MethodsHIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 T-cell count, interleukin-6, and alcohol use severity.ResultsThe sample of 84 virally suppressed MSM had a median CD4 T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05).ConclusionsMonocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.

Published
2018

31. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Author

Du, Jing, Paz, Katelyn, Flynn, Ryan, Vulic, Ante, Robinson, Tara M., Lineburg, Katie E., Alexander, Kylie A., Meng, Jingjing, Roy, Sabita, Panoskaltsis-Mortari, Angela, Loschi, Michael, Hill, Geoffrey R., Serody, Jonathan S., Maillard, Ivan, Miklos, David, Koreth, John, Cutler, Corey S., Antin, Joseph H., Ritz, Jerome, MacDonald, Kelli P., Schacker, Timothy W., Luznik, Leo, and Blazar, Bruce R.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results